XML 43 R8.htm IDEA: XBRL DOCUMENT v2.4.0.6
CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)
In Thousands, unless otherwise specified
 12 Months Ended 197 Months Ended
Dec. 31, 2012
Dec. 31, 2011
Dec. 31, 2010
Dec. 31, 2012
Operating activities:        
Net loss $ (13,186) $ (15,243) $ (16,021) $ (266,735)
Adjustments to reconcile net loss to net cash used in operating activities:        
Accretion of interest on notes payable, net of amortization of debt premium       100
Amortization of investment premiums, net       (2,297)
Change in valuation of derivative 23 20   351
Change in valuation of warrants (51) (629) 338 (6,706)
Non-cash consideration associated with stock purchase agreement 423     423
Depreciation 60 241 457 12,615
Amortization of intangible assets       886
Fixed asset impairment       221
Unrealized foreign exchange (gains) losses       7,747
Deferred revenue       (98)
Compensation for warrants issued to non-employees       1,215
Shares issued for IP rights       446
Loss (gain) on disposal of property, plant and equipment (62) 1 (13) 38
Goodwill and intangibles impairment       7,934
Stock-based compensation 380 882 1,746 19,403
Provision for restructuring       1,779
Amortization of issuance costs of Preferred Ordinary 'C' shares       2,517
Transaction costs on sale of Economic Rights 33     33
Gain on termination of distribution agreements (1,192)     (1,192)
Changes in operating assets and liabilities:        
Prepaid expenses and other assets (239) 174 516 (297)
Accounts payable and other current liabilities 1,768 577 (3,067) (3,545)
Net cash used in operating activities (12,043) (13,977) (16,044) (225,162)
Investing activities:        
Purchase of ALIGN       (3,763)
Purchase of property, plant and equipment (12) (6) (8) (8,849)
Proceeds from sale of property, plant and equipment 62 5 41 225
Purchase of short-term investments on deposit, net of maturities       (156,657)
Cash proceeds from redemption of short term securities       162,729
Net cash provided by (used in) investing activities 50 (1) 33 (6,315)
Financing activities:        
Payments of capital lease obligations       (3,719)
Proceeds from issuance of ordinary and preferred ordinary shares, net of issuance costs     30,820 121,678
Proceeds from issuance of common stock and warrants, net of issuance costs 3,881 9,267 2,576 95,552
Proceeds from the exercise of stock options and warrants, net of issuance costs 94 3   267
Payment of preferred stock dividend   (364)   (1,898)
Repayment of government loan       (455)
Government loan received       414
Loan received from Cyclacel Group plc       9,103
Proceeds of committable loan notes issued from shareholders       8,883
Loans received from shareholders       1,645
Cash and cash equivalents assumed on stock purchase of Xcyte       17,915
Costs associated with stock purchase       (1,951)
Net cash provided by financing activities 3,975 8,906 33,396 247,434
Effect of exchange rate changes on cash and cash equivalents (19) 26 617 455
Net increase (decrease) in cash and cash equivalents (8,037) (5,046) 18,002 16,412
Cash and cash equivalents, beginning of period 24,449 29,495 11,493  
Cash and cash equivalents, end of period 16,412 24,449 29,495 16,412
Cash received during the period for:        
Interest 10 31 11 11,756
Taxes 565 685 1,082 18,772
Cash paid during the period for:        
Interest     (155) (1,914)
Schedule of non-cash transactions:        
Acquisitions of equipment purchased through capital leases       3,470
Issuance of common shares in connection with license agreements       592
Issuance of Ordinary shares on conversion of bridging loan       1,638
Issuance of Preferred Ordinary 'C' shares on conversion of secured convertible loan notes and accrued interest       8,893
Issuance of Ordinary shares in lieu of cash bonus       164
Issuance of other long term payable on ALIGN acquisition       $ 1,122